AIM ImmunoTech financials
$0.1735−5.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $88.0K | $170.0K | $202.0K | $141.0K | $135.0K | $163.0K | $140.0K |
| Gross profit | -$40.0K | $139.0K | $160.0K | $141.0K | -$715.0K | -$643.0K | -$753.0K |
| Gross margin | −45.5% | 81.8% | 79.2% | 100.0% | −529.6% | −394.5% | −537.9% |
| Operating income | -$11.7M | -$19.8M | -$31.9M | -$19.9M | -$18.8M | -$15.2M | -$12.4M |
| Net income | -$14.0M | -$17.3M | -$29.0M | -$19.4M | -$19.1M | -$14.4M | -$9.4M |
| Net margin | −15861.4% | −10188.2% | −14337.6% | −13790.8% | −14168.1% | −8834.4% | −6717.1% |
| Diluted EPS | $-8.62 | $-30.92 | $-0.60 | $-0.40 | $-0.40 | $-0.45 | $-2.58 |
| EBITDA | -$11.5M | -$19.5M | -$31.7M | -$19.7M | -$16.3M | -$14.3M | -$11.7M |
| Operating cash flow | -$11.0M | -$14.9M | -$21.3M | -$16.1M | -$14.0M | -$10.4M | -$9.1M |
| Free cash flow | -$11.0M | -$14.9M | -$21.3M | -$16.2M | -$14.0M | -$10.4M | -$9.1M |
| Diluted shares | 1.6M | 0.6M | 48.6M | 48.1M | 47.4M | 31.9M | 3.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.0M | $1.7M | $5.4M | $27.1M | $32.1M | $38.5M |
| Short-term investments | $62.0K | $2.3M | $7.6M | $7.1M | $16.2M | $501.0K |
| Total debt | $4.5M | $2.3M | $0.00 | $0.00 | $0.00 | $2.1M |
| Total assets | $5.8M | $8.6M | $19.4M | $40.5M | $57.7M | $64.6M |
| Total liabilities | $15.6M | $9.9M | $9.1M | $2.0M | $820.0K | $3.3M |
| Shareholders' equity | -$9.8M | -$1.3M | $10.2M | $38.5M | $56.9M | $61.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology